Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 589.2 DKK -20.72% Market Closed
Market Cap: 2.6T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Gross Margin
Novo Nordisk A/S

84.7%
Current
84%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84.7%
=
Gross Profit
229.1B
/
Revenue
270.6B

Gross Margin Across Competitors

Country DK
Market Cap 2.6T DKK
Gross Margin
85%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 197.2B CHF
Gross Margin
73%
Country UK
Market Cap 159B GBP
Gross Margin
82%
Country CH
Market Cap 169.7B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
Country IE
Market Cap 147.1B USD
Gross Margin
68%
No Stocks Found

Novo Nordisk A/S
Glance View

Market Cap
2.6T DKK
Industry
Pharmaceuticals
Economic Moat
Wide

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84.7%
=
Gross Profit
229.1B
/
Revenue
270.6B
What is the Gross Margin of Novo Nordisk A/S?

Based on Novo Nordisk A/S's most recent financial statements, the company has Gross Margin of 84.7%.